AMALY — SHARIAH COMPLIANCE REPORT ================================== Symbol: LMAT Report Date: 2026-08-05 Full Report: https://amaly.io/stock/LMAT EXECUTIVE SUMMARY ------------------ Compliance Status: NON_COMPLIANT Quality Rating: BBB Description: LeMaitre Vascular, Inc. (LMAT) is a healthcare company specializing in medical devices for peripheral vascular disease treatment. This report evaluates its Shariah compliance across financial ratios, business activities, ESG factors, and index inclusions. While financial screens indicate strong compliance with low debt, liquidity, and impure income levels, the company is not included in major Shariah indices primarily due to market capitalization and liquidity criteria rather than screening failures. Business activities are fully permissible, with no non-compliant revenue sources identified. Overall, LMAT presents a moderate compliance profile suitable for review by Shariah scholars. Primary Compliance Concerns: - Exclusion from all major Shariah indices due to size and liquidity thresholds, despite passing financial screens - Limited transparency on subsidiary operations and detailed debt instruments Purification Requirement: 2.91% Index Inclusion: Not included in S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, or Dow Jones Islamic Market (DJIM) KEY FINANCIAL METRICS ---------------------- Debt Ratio: 9.3% Liquidity Ratio: 15.2% Interest Income Ratio: 2.9% Purification Required: 2.91% INDEX INCLUSION STATUS ----------------------- S&P Shariah: EXCLUDED MSCI Islamic: EXCLUDED DJIM: EXCLUDED FTSE Shariah: EXCLUDED Total: 0 of 4 Last Verified: 2026-01-15 REPORTING PERIOD ----------------- Latest Annual Report: FY 2025 Latest Quarterly Data: Q4 2025 Trend Period: FY 2020 to FY 2025 Data Retrieved: 2026-03-01T12:00:00Z --- Full interactive report: https://amaly.io/stock/LMAT Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.